Key result
De-escalation of oral P2Y12 receptor inhibitors to clopidogrel currently lacks definitive efficacy and safety results to support its routine use in clinical practice.
Why the study?
De-escalation of novel P2Y12 inhibitors to clopidogrel occurs in practice, but a lack of definitive efficacy or safety results remains an obstacle to routinely suggesting this strategy.
Does de-escalation of oral P2Y12 receptor inhibitors (prasugrel or ticagrelor) to clopidogrel improve safety without compromising efficacy?
Does de-escalation of oral P2Y12 receptor inhibitors (prasugrel or ticagrelor) to clopidogrel improve safety without compromising efficacy?
While de-escalation of P2Y12 inhibitors to clopidogrel is common in practice to reduce bleeding and costs, definitive evidence is still needed to recommend it routinely.
Answers are grounded in this paper and cite their sources.
Warrants continued potent P2Y12 inhibitor use; leaves open net benefit of de-escalation pending definitive trials.
receptor inhibitors, prasugrel and ticagrelor, are proposed as "first-line" antiplatelet agents in the absence of contraindications and up to a year from the index event. However, de-escalation of treatment to clopidogrel occurs with a variable frequency in real-life practice, most commonly due to an increased bleeding potential, more frequent side effects, and a higher cost for the novel agents. Pharmacodynamic studies provide most of the data on guidance for de-escalation. Despite positive messages from recent trials and registries, lack of definitive efficacy or safety results of such a strategy remains an obstacle to suggest de-escalation in a routine basis. Carefully designed studies are likely to improve our understanding of the impact of de-escalation and help to better define its position in current pharmacotherapy.
No takes yet. Share an insight, caveat, or question.
Alexopoulos et al. (2019) conducted a review in Patients requiring oral P2Y12 receptor inhibitors. De-escalation to clopidogrel was evaluated. De-escalation of oral P2Y12 receptor inhibitors to clopidogrel currently lacks definitive efficacy and safety results to support its routine use in clinical practice.
Synapse has enriched 10 related papers. Consider them for comparative context: